Patent · US Active

Anti-αβTCR antibody

US11186638B2 · kind B2 · utility

7Cited by

40References

11Claims

0Family size

Assignee

Genzyme Corporation · US

Inventors

Daniel Snell · Thalwil, CH
Andreas Menrad · Berlin, DE
Gina Lacorcia · Concord, US
Srinivas Shankara · Shrewsbury, US
Huawei Qiu · Westborough, US
Clark Pan · Sudbury, US
Benjamin Kebble · Zürich, CH

Key dates

Filing date	Jan 10, 2018
Grant date	Nov 30, 2021
Priority date	—
Expiry date	Apr 26, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.